ArticleDiscover oncology2026
Integrative multi-omics analysis identifies a circadian rhythm-associated gene signature for prognosis and therapeutic stratification in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCircadian rhythm disruption is increasingly implicated in tumor progression and therapy resistance. However, its prognostic value and impact on the tumor immune microenvironment in lung adenocarcinoma (LUAD) remain unclear. This study aimed to develop a robust circadian rhythm-based gene signature to improve risk stratification and inform personalized therapeutic strategies in LUAD.
methodsWe integrated multi-omics data from over 900 LUAD patients across TCGA and GEO databases. A circadian rhythm-related gene prognostic signature (CRGPS) was constructed from candidate genes using ten machine learning algorithms and validated externally. The tumor immune microenvironment, mutation landscape, and therapy response were analyzed using bioinformatics algorithms. Single-cell RNA sequencing data were utilized to explore gene expression at cellular resolution.
resultsA 10-gene CRGPS was developed, which effectively stratified patients into high- and low-risk groups with significantly divergent overall survival in both training and validation cohorts. Unsupervised clustering based on these genes revealed two molecular subtypes (C1 and C2) with distinct characteristics. The two subgroups exhibited significant differences in terms of the tumor immune microenvironment, clinical prognosis, and therapeutic sensitivity. Single-cell analysis localized key signature genes to endothelial and epithelial cells and revealed enhanced endothelial-endothelial communication.
conclusionsThe CRGPS serves as a robust prognostic framework for risk stratification and provides hypothesis-generating insights into therapeutic vulnerabilities based on in silico predictions of immune profiles and drug sensitivity, pending prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.